| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1022484639 |
| P356 | DOI | 10.1007/S10637-011-9666-9 |
| P698 | PubMed publication ID | 21484248 |
| P50 | author | Kiyohiko Hatake | Q88491888 |
| P2093 | author name string | Ken Kobayashi | |
| Nobuyuki Yamamoto | |||
| Tomonori Hirashima | |||
| Akira Fukutomi | |||
| Sakura Sakajiri | |||
| Kaoru Matsui | |||
| Hiromi Tanii | |||
| P2860 | cites work | Anticancer activities of histone deacetylase inhibitors | Q29616624 |
| Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies | Q33369463 | ||
| Mechanisms of HDAC inhibitor-induced thrombocytopenia | Q33375868 | ||
| GATA-factor dependence of the multitype zinc-finger protein FOG-1 for its essential role in megakaryopoiesis | Q34034571 | ||
| Histone deacetylase inhibitors in cancer therapy | Q34659283 | ||
| Development of fetal haemoglobin-blood cells (F cells) within colorectal tumour tissues | Q35770057 | ||
| Molecularly targeted oncology therapeutics and prolongation of the QT interval | Q36896867 | ||
| Development of the pan-DAC inhibitor panobinostat (LBH589): successes and challenges | Q37432654 | ||
| Clinical studies of histone deacetylase inhibitors. | Q37512917 | ||
| Histone deacetylase inhibitor panobinostat induces clinical responses with associated alterations in gene expression profiles in cutaneous T-cell lymphoma | Q40070617 | ||
| Preliminary evidence of disease response to the pan deacetylase inhibitor panobinostat (LBH589) in refractory Hodgkin Lymphoma. | Q43296400 | ||
| Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma: multinational phase II-III trial results | Q43594172 | ||
| Induction of fetal hemoglobin expression by the histone deacetylase inhibitor apicidin | Q44189616 | ||
| Targeting tumor angiogenesis with histone deacetylase inhibitors: the hydroxamic acid derivative LBH589. | Q46905304 | ||
| Challenges of evaluating the cardiac effects of anticancer agents | Q79834443 | ||
| P433 | issue | 3 | |
| P304 | page(s) | 1096-1106 | |
| P577 | publication date | 2011-04-12 | |
| P1433 | published in | Investigational New Drugs | Q2312231 |
| P1476 | title | A phase I study of oral panobinostat (LBH589) in Japanese patients with advanced solid tumors | |
| P478 | volume | 30 |
| Q37475206 | Celastrol increases glucocerebrosidase activity in Gaucher disease by modulating molecular chaperones. |
| Q33443179 | Clinical Pharmacokinetics and Pharmacodynamics of Panobinostat |
| Q38844615 | Clinical pharmacokinetics of panobinostat, a novel histone deacetylase (HDAC) inhibitor: review and perspectives |
| Q58800432 | Differences in Functional Expression of Connexin43 and Na1.5 by Pan- and Class-Selective Histone Deacetylase Inhibition in Heart |
| Q91176638 | Fimepinostat, a novel dual inhibitor of HDAC and PI3K, effectively reverses HIV-1 latency ex vivo without T cell activation |
| Q35214924 | Histone deacetylase inhibitors in clinical studies as templates for new anticancer agents |
| Q37260402 | Influence of a novel histone deacetylase inhibitor panobinostat (LBH589) on the growth of ovarian cancer |
| Q33426983 | Panobinostat PK/PD profile in combination with bortezomib and dexamethasone in patients with relapsed and relapsed/refractory multiple myeloma |
| Q51034578 | Panobinostat as Pan-deacetylase Inhibitor for the Treatment of Pancreatic Cancer: Recent Progress and Future Prospects. |
| Q33408889 | Panobinostat in lymphoid and myeloid malignancies |
| Q38403118 | Panobinostat: first global approval |
| Q33397434 | Phase I dose-escalating study of panobinostat (LBH589) administered intravenously to Japanese patients with advanced solid tumors |
| Q33402040 | Phase I study of bevacizumab, everolimus, and panobinostat (LBH-589) in advanced solid tumors |
| Q40047158 | Phase I study of panobinostat and 5-azacitidine in Japanese patients with myelodysplastic syndrome or chronic myelomonocytic leukemia |
| Q33412724 | Phase I study of panobinostat and imatinib in patients with treatment-refractory metastatic gastrointestinal stromal tumors |
| Q35603293 | Population pharmacokinetics of intravenous and oral panobinostat in patients with hematologic and solid tumors |
| Q26771601 | Potential of apoptotic pathway-targeted cancer therapeutic research: Where do we stand? |
| Q37324186 | Profile of panobinostat and its potential for treatment in solid tumors: an update |
| Q38582589 | Targeting Chromatin-Mediated Transcriptional Control of Gene Expression in Non-Small Cell Lung Cancer Therapy: Preclinical Rationale and Clinical Results |
| Q36245380 | Targeting triple-negative breast cancer cells with the histone deacetylase inhibitor panobinostat |
| Q38071321 | Toxicological and metabolic considerations for histone deacetylase inhibitors |
| Q27000542 | Trials with 'epigenetic' drugs: an update |
| Q35001758 | Triple-negative breast cancer: new perspectives for targeted therapies. |
| Q92408464 | Understanding Apoptosis and Apoptotic Pathways Targeted Cancer Therapeutics |
Search more.